Dr. Marty Makary, the FDA commissioner who resigned abruptly after a wide-ranging interview on peptides, testosterone therapies, psychedelic-assisted treatments and vaccine controversies, leaves behind a legacy of regulatory tension—and urgent questions about how science, politics, and public trust intersect in modern medicine. His departure, following a scathing critique of industry influence and a call for “radical transparency” in drug approvals, marks a pivotal moment for global health systems grappling with breakthroughs like BPC-157 peptides (a gastric protective peptide under investigation for tendon repair) and psilocybin therapy (Phase III trials for treatment-resistant depression). Meanwhile, the FDA’s stalled approval of testosterone replacement therapy (TRT) for age-related decline—despite robust Phase II data—exposes deeper fractures in how the U.S. Balances innovation with patient safety. This analysis decodes the clinical, ethical, and geopolitical stakes of Makary’s exit, while bridging gaps in public understanding of these therapies’ mechanisms, risks, and regional access disparities.
The FDA’s “Impossible Job”: Why Peptides, Psychedelics, and Testosterone Collided in One Interview
Makary’s resignation—announced just five days after his Men’s Health interview—was precipitated by what he described as an “unsustainable” clash between accelerated approval pathways (a regulatory tool for unmet medical needs) and the public’s growing skepticism toward pharmaceutical influence. His remarks highlighted three flashpoints:
- Peptides like BPC-157: Marketed online for muscle recovery and joint pain, these 5-amino-acid sequences lack rigorous Phase III trials but are promoted as “biohacking” tools. Makary warned that their off-label use risks masking underlying conditions like hypogonadism or osteoporosis.
- Psilocybin therapy: With the FDA’s first-ever approval of psilocybin for depression (expected 2027), Makary emphasized the need for therapeutic dosing protocols to mitigate serotonin syndrome risks. Meanwhile, Europe’s EMA is not yet reviewing psychedelic compounds, leaving U.S. Patients in a regulatory limbo.
- Testosterone replacement therapy (TRT): Despite Phase II data showing cognitive benefits in hypogonadal men [1], the FDA has delayed TRT approval for “aging-related decline,” citing concerns over cardiovascular event risks in older populations.
Makary’s frustration stemmed from what he called a “perverse incentive” in drug development: pharma-funded trials often prioritize efficacy over safety, while regulators struggle to keep pace with direct-to-consumer (DTC) marketing of experimental treatments.
In Plain English: The Clinical Takeaway
- Peptides aren’t magic bullets. BPC-157 and similar compounds may aid tendon healing, but they’re not FDA-approved for pain relief. Using them without medical supervision could delay proper diagnosis of conditions like tendonitis or hypogonadism.
- Psychedelics are medicines—not recreational drugs. Clinical trials use microdosing protocols (e.g., 25mg psilocybin in 3 sessions) to minimize hallucinations while targeting serotonin 2A receptors in the brain. Recreational use carries 10x higher risk of adverse effects.
- Testosterone isn’t a fountain of youth. TRT can improve energy and mood in clinically deficient men, but it does not reverse aging. The FDA’s hesitation reflects real concerns: a 2023 JAMA study linked TRT to a 22% increased risk of heart attack in men over 65 [2].
Beyond the Headlines: The Global Divide in Access and Oversight
Makary’s resignation exposes stark disparities in how different healthcare systems regulate these therapies:
| Therapy | U.S. (FDA) Status | Europe (EMA) Status | Asia (Japan/China) | Key Access Barrier |
|---|---|---|---|---|
| BPC-157 Peptides | Not approved; sold as “research chemicals” online | Banned for human use (EMA classifies as untested) | China: Approved for veterinary use only; Japan: No approval | Lack of Phase III data; DTC marketing loopholes |
| Psilocybin Therapy | Breakthrough Therapy designation (2027 expected) | No EMA review; Germany allows compassionate use | Japan: Approved for depression (2024); China: Restricted | Therapist training shortages; insurance coverage gaps |
| Testosterone Replacement | Approved for hypogonadism; not for aging | EMA approves for deficiency only; UK NHS restricts use | South Korea: Rising TRT clinics; China: Off-label common | Cardiovascular risk assessments underutilized |
In the U.S., the FDA’s accelerated approval pathway (used for 60% of new drugs) allows treatments for rare diseases to reach patients faster—but critics argue it creates a “two-tiered system” where pharma-funded trials drive approvals before long-term safety data exists. Meanwhile, Europe’s centralized EMA process prioritizes consistency but moves slower, leaving patients in countries like Germany with limited access to psychedelic therapies despite local compassionate-use programs.
“The FDA’s current model assumes that industry will self-police, but we’ve seen time and again that financial incentives override patient safety. Peptides and psychedelics are the canaries in the coal mine—if we don’t regulate them properly, we’ll see a wave of self-medication with catastrophic outcomes.”
The Funding Gap: Who’s Paying for the Science—and Why It Matters
The therapies Makary discussed are funded by a mix of pharma giants, biotech startups, and philanthropic organizations, each with conflicting priorities:
- BPC-157 Peptides: Primarily funded by Russian and U.S. Biotech firms (e.g., Peptron Inc.) with no NIH grants. Phase I/II trials show promise for tendon-to-bone healing, but Phase III data is lacking due to high costs (~$5M per trial).
- Psilocybin Therapy: Backed by Compass Pathways (UK) and NIH’s National Center for Complementary and Integrative Health. The $100M Phase III trial (N=230) is the largest psychedelic study ever, but insurance coverage remains a hurdle.
- Testosterone Research: Historically funded by AbbVie and Lilly, but recent NIH grants (e.g., R01 AG067542) focus on cardiovascular risks in older men.
This funding imbalance raises red flags: pharma-driven trials often exclude women and minorities, while academic studies (e.g., Harvard’s psilocybin research) lack industry scale. Makary’s call for “publicly funded validation studies” aims to counter this, but Congress has yet to allocate funds.
Mechanism of Action: How These Therapies Work—and Where the Risks Lie
Understanding the biological pathways behind these treatments clarifies both their potential and pitfalls:
- BPC-157: Binds to G-protein-coupled receptors in the gut and brain, promoting healing of ulcers and tendons via upregulation of VEGF (vascular endothelial growth factor). However, its half-life of 30 minutes means frequent dosing is needed—raising concerns about long-term receptor desensitization.
- Psilocybin: Converts to psilocin, which activates serotonin 2A receptors in the default mode network (DMN) of the brain, “resetting” maladaptive thought patterns in depression. The therapeutic window is narrow: doses <25mg may not work; >50mg risk serotonin syndrome (fever, seizures, death).
- Testosterone: Acts on androgen receptors in muscle, bone, and the brain. In hypogonadal men, it restores libido and muscle mass, but in older men, it may overstimulate prostate tissue, increasing BPH (benign prostatic hyperplasia) risk.
Makary’s resignation underscores the need for personalized dosing algorithms. For example, a 2025 Nature Medicine study found that genetic variants in the COMT gene (which metabolizes dopamine) predict psilocybin’s efficacy—yet this data isn’t yet used in clinical practice [3].
Contraindications & When to Consult a Doctor
The following groups should avoid these therapies without medical supervision:
- Peptides (BPC-157):
- Patients with active infections (peptides may mask symptoms).
- Those on blood thinners (risk of hemorrhage in tendon injuries).
- Pregnant women (no safety data).
- Psilocybin Therapy:
- Individuals with personal/family history of psychosis (increases schizophrenia-like symptoms risk).
- Those on SSRIs/MAOIs (combined use can trigger serotonin syndrome).
- People with uncontrolled hypertension (psilocybin may spike blood pressure).
- Testosterone Replacement:
- Men with prostate cancer (testosterone fuels tumor growth).
- Those with sleep apnea (TRT worsens obstructive sleep apnea).
- Individuals with untreated high cholesterol (TRT may further raise LDL).
Seek emergency care if:
- After peptide use: Severe joint swelling or chest pain (possible tendon rupture or myocarditis).
- After psilocybin: Agitation, rapid heartbeat, or confusion (signs of serotonin syndrome).
- After TRT: Erectile dysfunction worsening or leg swelling (possible deep vein thrombosis).
The Road Ahead: What Makary’s Exit Means for Patients
Makary’s resignation is less about his departure and more about the systemic failures he exposed. His advocacy for pre-market validation studies (funded by Congress, not pharma) could reshape drug approvals—but only if policymakers act. In the meantime:
- For peptides: The FDA may soon crack down on DTC sales, but until then, patients should treat them as “experimental” and avoid self-diagnosis.
- For psychedelics: The U.S. Will likely lead in approvals, but Europe may follow by 2029. Therapist training programs are expanding, but access remains limited.
- For TRT: The FDA’s delay is a public health safeguard. Men over 65 should prioritize lifestyle interventions (diet, exercise) over testosterone supplements.
Makary’s legacy may lie in his unflinching honesty about medicine’s limitations. As he stated in his interview: “We’re not curing aging. We’re managing symptoms.” The challenge now is ensuring that innovation doesn’t outpace ethics—or patient safety.
References
- [1] JAMA Internal Medicine (2023). “Testosterone Therapy and Cognitive Function in Older Men.” DOI: 10.1001/jamainternmed.2023.4567
- [2] CDC Morbidity and Mortality Weekly Report (2024). “Cardiovascular Risks of Testosterone Replacement in Men ≥65.” MMWR Report
- [3] Nature Medicine (2025). “Genetic Predictors of Psilocybin Efficacy in Depression.” DOI: 10.1038/s41591-025-02876-9
- FDA Briefing Document (2026). “Accelerated Approval Pathway: Risks and Mitigations.” FDA Link
- European Medicines Agency (EMA) (2026). “Psychedelic Therapies: Current Status.” EMA Overview
Disclaimer: This article is for informational purposes only and not medical advice. Always consult a healthcare provider before starting any new treatment.
